UNJ.F The United Laboratories International Holdings Limited
- Market cap
- EUR 1.71B
- P/E
- 29.0x
- P/B
- 0.75x
- ROE
- 12.0%
- Dividend yield
- 3.82%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is UNJ.F undervalued?
Graham numberUNJ.F trades 1.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
The United Laboratories International Holdings Limited fundamental analysis
No fundamental analysis for The United Laboratories International Holdings Limited yet.
The United Laboratories International Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium prod…
Full company profileThe United Laboratories International Holdings Limited financial statements
The United Laboratories International Holdings Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.32B | 6.83B | 7.51B | 8.39B | 8.77B | 9.70B | 11.3B | 13.7B | 13.8B | 13.2B |
| Gross Profit | 2.25B | 2.50B | 3.05B | 3.62B | 3.81B | 4.21B | 4.97B | 6.33B | 6.08B | 5.51B |
| Operating Income | 504M | 761M | 1.01B | 1.09B | 1.32B | 1.47B | 2.09B | 3.29B | 3.12B | 2.48B |
| EBITDA | - | 1.13B | 1.79B | 1.80B | 1.06B | 1.26B | 2.64B | 3.98B | 3.94B | 3.25B |
| Net Income | -279M | 81.8M | 683M | 642M | 703M | 988M | 1.58B | 2.70B | 2.66B | 2.09B |
| EPS | - | 0.05 | 0.42 | 0.39 | 0.38 | 0.54 | 0.87 | 1.49 | 1.46 | 1.06 |
| Balance Sheet | ||||||||||
| Total Assets | 14.9B | 14.1B | 14.6B | 15.7B | 15.0B | 16.3B | 19.0B | 21.0B | 25.8B | 30.9B |
| Total Liabilities | 9.58B | 8.67B | 8.48B | 9.03B | 6.35B | 6.99B | 8.37B | 8.27B | 11.4B | 13.4B |
| Shareholders' Equity | 5.35B | 5.44B | 6.12B | 6.67B | 8.61B | 9.34B | 10.6B | 12.7B | 14.4B | 17.4B |
| Cash & Short-term Investments | 1.78B | 1.59B | 1.58B | 3.16B | 3.00B | 3.33B | 4.74B | 4.26B | 6.33B | 10.6B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.07B | 770M | 1.21B | 1.80B | 1.57B | 1.54B | 2.03B | 2.44B | 3.20B | 3.75B |
| Capital Expenditure | 485M | 458M | 512M | 431M | 531M | 482M | 818M | 1.46B | 1.87B | 2.89B |
| Free Cash Flow | - | 296M | 658M | 1.35B | 1.03B | 1.06B | 1.21B | 978M | 1.33B | 855M |
| Ratios | ||||||||||
| ROE | -5.2% | 1.5% | 11.2% | 9.6% | 8.2% | 10.6% | 14.9% | 21.2% | 18.5% | 12.0% |
| ROA | -1.9% | 0.6% | 4.7% | 4.1% | 4.7% | 6.1% | 8.3% | 12.9% | 10.3% | 6.8% |
| Net Profit Margin | -4.4% | 1.2% | 9.1% | 7.6% | 8.0% | 10.2% | 13.9% | 19.7% | 19.3% | 15.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
The United Laboratories International Holdings Limited dividends
- Dividend yield
- 3.82%
- Forward dividend
- 0.03 EUR
- Payout ratio
- 50.0%
- Ex-dividend date
- Jul 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.04B | 0.53 | 50.0% |
| 2024 | CNY 1.02B | 0.56 | 38.3% |
| 2023 | CNY 581M | 0.32 | 21.5% |
| 2022 | CNY 273M | 0.15 | 17.2% |
| 2021 | CNY 221M | 0.12 | 22.4% |
| 2020 | EUR 128M | 0.07 | 18.2% |
| 2019 | EUR 98.4M | 0.06 | 15.3% |
| 2018 | EUR 84.4M | 0.05 | 12.4% |
| 2017 | EUR 84.4M | 0.05 | 103.3% |
| 2016 | EUR 84.4M | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns The United Laboratories International Holdings Limited
- Insiders 44.48%
- Institutions 19.58%
- Public & others 35.94%
- Shares outstanding 1.97B
- Free float 1.09B
The United Laboratories International Holdings Limited company profile
- Company name
- The United Laboratories International Holdings Limited
- Ticker
- UNJ.F
- ISIN
- KYG8813K1085
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 18,000
- Fiscal year end
- December
- Address
- 6 Fuk Wang Street, Yuen Long, Hong Kong
- Phone
- 852 2687 1033
- Website
- tul.com.cn
About The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-infection, and other human-used finished products, including ophthalmic drugs, topical dermatological drugs, etc.; and health and wellness products, such as general dietary supplements, healthcare food products, cross-border nutritional supplements, and medical and aesthetic skincare products for various categories comprising bone and joint nutrition, intestinal regulation, cardiovascular health, vision protection, and immunity enhancement. Further, it is involved in the research and development, production, sale, and technical services of economic and companion animal medicines for livestock, poultry, and aquatic products and pets. The company has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The United Laboratories International Holdings Limited was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
The United Laboratories International Holdings Limited management
8- Mr. Hoi Shan TsoiExecutive Chairman · born 1978
- Mr. Wing Hon Leung CPA, FCPAVice Chairman, CFO & Company Secretary · born 1962
- Ms. Xian Hong ZouVP & Executive Director · born 1965
- Ms. Siu Chit ChoyGlobal Director of Intermediate & Bulk Medicine and Executive Director · born 1973
- Ms. Karen YangInvestor Relationship Director
- Mr. Wen Yu ZhangGeneral Manager of United Laboratories (Inner Mongolia) Limited · born 1969
- Mr. Yu Bo HanGeneral Manager of Zhuhai United Laboratories Co., Ltd · born 1974
- Mr. Chun Lai CaoGeneral Manager of United Bio-Technology (Hengqin) Co., Ltd · born 1979